No price history available.
Key financial summary
Financials in TRY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TRYm | 1,014 | 2,021 | 5,237 | 6,039 | 4,867 | 6,151 | N/A | N/A |
| Operating profit | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TRYm | 179 | 319 | 802 | -878 | -2,727 | -4,046 | N/A | N/A |
| EPS reported | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TRYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TRY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TRY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Hektas Ticaret T.A.S., founded in 1956 and headquartered in Gebze, Turkey, is a leading Turkish company that manufactures, imports, and distributes a wide spectrum of agricultural and veterinary products. For the agricultural sector, their offerings include an extensive range of crop protection solutions such as fungicides, herbicides, insecticides, acaricides, biological insecticides, fumigants, nematicides, soil fumigants, and plant growth regulators. They also provide specialized winter care treatments, summer oils, and spreading agents. Furthermore, Hektas supplies various fertilizers, including foliar applications, organo-mineral compounds, and drip irrigation products, alongside other farming essentials and even tomato seeds. In the animal health domain, the company offers a diverse portfolio of veterinary pharmaceuticals, encompassing antibacterials, vitamin and mineral supplements, feed additives, anti-inflammatory drugs, and anti-parasitics. Their product line additionally features poultry health remedies, pet care items, and pet food.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hektas Ticaret T.A.S. (HEKTS.IS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Hektas Ticaret T.A.S., founded in 1956 and headquartered in Gebze, Turkey, is a leading Turkish company that manufactures, imports, and distributes a wide spectrum of agricultural and veterinary products. For the agricultural sector, their offerings include an extensive range of crop protection solutions such as fungicides, herbicides, insecticides, acaricides, biological insecticides, fumigants, nematicides, soil fumigants, and plant growth regulators. They also provide specialized winter care treatments, summer oils, and spreading agents. Furthermore, Hektas supplies various fertilizers, including foliar applications, organo-mineral compounds, and drip irrigation products, alongside other farming essentials and even tomato seeds. In the animal health domain, the company offers a diverse portfolio of veterinary pharmaceuticals, encompassing antibacterials, vitamin and mineral supplements, feed additives, anti-inflammatory drugs, and anti-parasitics. Their product line additionally features poultry health remedies, pet care items, and pet food.